Skip to content

Study examining the PROMUS Element everolimus-eluting stent in multi-center Coronary Intervention of complex Arterial Lesion Subsets (OCT and IVUS sub analysis)

Study examining the PROMUS Element everolimus-eluting stent in multi-center Coronary Intervention of complex Arterial Lesion Subsets (OCT and IVUS sub analysis) - SPECIALIST registry

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000021122
Enrollment
50
Registered
2016-02-21
Start date
2012-08-15
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex coronary artery disease

Interventions

Sponsors

The PCI Guideline Research Society
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: a. Ischemic heart disease including stable angina pectoris and acute coronary syndrome b. Male or non-pregnant female c. Key lesion inclusion criteria as follows (1) Multi-vessel diseases (2) Long lesion (lesion length >30mm by visual estimation) (3) Small vessel disease (reference diameter <2.5mm by visual estimation) (4) Bifurcation lesion (5) Calcified lesion (6) Protected or non-protected left main trunk disease

Exclusion criteria

Exclusion criteria: (1) Chronic total occlusion (2) In stent restenosis of bare metal stent or everolimus-eluting stent (3) Ostial lesion (4)Excessive tortuosity proximal to or within the lesion (5)Extreme angulation proximal to or within the lesion (6)Lesion is not an acceptable candidate for Optical Coherence Tomography

Design outcomes

Primary

MeasureTime frame
% stent struts uncovered at 9 month as measured by OCT

Secondary

MeasureTime frame
% stent struts uncovered at 24 month as measured by OCT

Countries

Japan

Contacts

Public ContactKenya Nasu

Toyohashi Heart Center Cardiology

yuyatomoya@gmail.com0532-37-3377

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026